ANGPTL3抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A375 cell lysate, Primary antibody: P07077(ANGPTL3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07077(ANGPTL3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

ANGPTL3 (angiopoietin-like protein 3) is a liver-secreted glycoprotein that regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), thereby modulating plasma triglyceride and cholesterol levels. Its role in lipid homeostasis has made it a promising therapeutic target for dyslipidemias, particularly in patients with familial hypercholesterolemia or refractory hypertriglyceridemia.

ANGPTL3-targeting monoclonal antibodies, such as evinacumab, bind to ANGPTL3 to block its inhibitory effects on LPL and EL. This mechanism enhances lipase activity, reducing circulating triglycerides and LDL cholesterol while increasing HDL cholesterol. Preclinical studies demonstrated that ANGPTL3 inhibition ameliorates atherosclerosis in animal models. Clinical trials confirmed its efficacy, with evinacumab receiving FDA approval in 2021 for homozygous familial hypercholesterolemia.

The development of ANGPTL3 antibodies reflects a shift toward novel lipid-lowering strategies beyond traditional statins or PCSK9 inhibitors. Their potential extends to treating metabolic syndromes and cardiovascular diseases linked to lipid dysregulation. Ongoing research explores broader applications, including combination therapies and genetic lipid disorders, underscoring ANGPTL3's significance as a multifunctional metabolic regulator.